by Candice Lim “Mommy, I don’t wanna take the shot,” whimpered the little girl in my clinic this morning. She was dressed all in pink and didn’t look more than five years old. “Please be a good girl, Leila. It’s not gonna hurt,” coaxed her […]
Issue 12 / 2016
by Suet Lin Chia At a Glance: Cancer has been haunting the human population for centuries. Despite the availability of various current treatments, the number of cancer patients is on the rise. This article discusses an alternative treatment for cancer– cancer virotherapy, a concept of using […]
From the 1st to 13th of March 2015, Scientific Malaysian organised an Ask Me Anything (AMA) session on their online discussion platform with Dr. Betty Kim Lee Sim (@bkimleesim), Founder of Protein Potential LLC and Executive Vice President of Process Development and Manufacturing at Sanaria […]
Although the Phase III clinical studies showed that Dengvaxia® was efficacious with satisfactory safety profile, we still have to continue monitoring the vaccine for long-term adverse effect by developing suitable models and active collaborations to decipher the immunological mechanisms that might be triggered by the vaccine. We also require a thorough cost-benefit analysis to determine the best option for dengue vaccination program in Malaysia. Besides, we should not neglect other approaches such as vector control and dengue hotspot identification that can benefit other mosquito-borne diseases (e.g. malaria).
Professor Mark Stoneking is a world-renowned geneticist in the field of human evolution. He (along with Professor Rebecca Cann and the late Professor Allan Wilson) is known for proposing the Mitochondrial Eve hypothesis in 1987. We caught up with Prof. Stoneking while he was in Malaysia to give a talk at the Monash University Malaysia in March 2015. This is part II of the interview.